Skip to main content
Clinical Trials/NCT00310479
NCT00310479
Completed
N/A

Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer

AHS Cancer Control Alberta1 site in 1 country16 target enrollmentJune 2006
ConditionsProstate Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
AHS Cancer Control Alberta
Enrollment
16
Locations
1
Primary Endpoint
characteristic metabolic pattern of prostate cancer at 3Tesla
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

We seek to develop an advanced imaging approach to identifying and localizing prostate cancer. We believe that high field MRI (magnetic resonance imaging) has the potential to do this and we will endeavor to prove this by having patients with prostate cancer pre-operatively undergo a technique called magnetic resonance spectroscopy. After surgery, the microscopic locations of cancer will be compared with the pre-operative images to assess how well the imaging technique succeeds.

Detailed Description

The proposed research is enormously relevant to the clinical understanding of early prostate cancer. We propose to test to see whether characteristic patterns of invivo 3T MRSI associated metabolites can be identified in correlation with clinically active tumor reserved on histopathologic analysis of resected specimens. We also plan to demonstrate that 3T MR spectra of prostate cancer will allow for more detailed metabolic assessment with higher sensitivity, specificity and accuracy and publish results established from MR spectra using 1.5T MR units. Functional imaging (eg. molecular imaging such as this) is felt to be the clinical wave of the future for cancer imaging, and if successful, will assume a very major role in the detection, assessment, treatment planning and delivery of drugs, radiation, heat and novel therapeutics in the fight against prostate cancer.

Registry
clinicaltrials.gov
Start Date
June 2006
End Date
March 2008
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Histologically verified prostate cancer
  • Patient has opted for surgery
  • Low risk prostate cancer PSA \<1 0, Gleason \< 7, Stage \< T2b
  • No contraindication to MR scanning
  • No prior history of malignancy
  • Fit for surgery

Exclusion Criteria

  • Nonbiopsied lesion
  • Intermediate or high risk prostate cancer
  • Unfit for surgery
  • Contraindication to MR scanning (i.e. pacemaker, aneurysm clips, claustrophobia)

Outcomes

Primary Outcomes

characteristic metabolic pattern of prostate cancer at 3Tesla

Secondary Outcomes

  • PPV of MRS in the detection of prostate cancer
  • specificity, accuracy, NPV

Study Sites (1)

Loading locations...

Similar Trials